Health products policy and standards
Our team provides authoritative guidance and standards on quality, safety and efficacy of health products and supports countries to formulate evidence-based policies and ensure good practice throughout the value chain.
/health-product-policy-and-standards-(hps)/63022.jpg?sfvrsn=e93c78d1_9 "Ministry of Health staff at their office in Port Vila")
/health-product-policy-and-standards-(hps)/who_034416-sm.jpg?sfvrsn=fc08f9ca_4 "WHO_034416 sm")
/health-product-policy-and-standards-(hps)/70820.jpg?sfvrsn=6b0fda4c_1 "70820")
Expert Committees
Advisory groups
WHO Technical Advisory Group on the COVID-19 Technology Access Pool
WHO has established a Technical Advisory Group (TAG) to advise on scientific, technical and strategic matters related to the COVID-19 Technology Access Pool (C-TAP).
Databases
Publications
All →
3 October 2025
WHO Drug Information - Volume 39, No. 3
The Third issue of volume 39 for 2025 includes:Consultation Documents: Cefiderocol sulfate tosilate (cefiderocoli sulfas tosilatum) Cefiderocol powder...
23 September 2025
Availability, price and affordability of health technologies for the management of diabetes
The WHO list of priority medical devices for management of cardiovascular diseases and diabetes, https://iris.who.int/handle/10665/341967, describes those...
5 September 2025
The selection and use of essential medicines, 2025: WHO AWaRe (Access, Watch, Reserve) classification...
The AWaRe classification is intended as a tool for monitoring antibiotic use, defining targets and monitoring the impact of stewardship policies and interventions...
5 September 2025
The selection and use of essential medicines, 2025: WHO Model List of Essential Medicines for Children,...
Essential medicines are those that satisfy the priority health care needs of a population. They are selected with due regard to disease prevalence and...
Journal articles
Evolution of Ebola and Marburg Treatment Centers Design, a Review of the Last Ten Years of Outbreaks in Africa
Architecture 2024, 4(4), 930-947
Disease foci of pharmaceutical research and development as reflected in applications for International Nonproprietary Names, 1953–2022
Bulletin of the World Health Organization, Volume 103, Number 1, January 2025 1-80
WHO-listed authorities (WLA) framework: transparent evidence-based approach for promoting regulatory reliance towards increased access to quality-assured medical products
Frontiers in Medicine, 23 September 2024 Sec. Regulatory Science
